P29.06 Both Endostar and Amifostine Reduced All the Incidence of Pneumonitis Above Grade 2 in Chemoradiotherapy With Locally Advanced NSCLC

The acceptable treatment strategy currently in the of locally advanced non-small cell lung cancer (LA-NSCLC) patients is combination treatment, but concurrent chemoradiotherapy (CCRT) has been associated with significant toxicities. aim this study was to assess ability Endostar and amifostine (AM) reduce incidence chemoradiotherapy-induced pneumonitis above grade 2 stage III NSCLC. Patients NSCLC from December 2008 2017 were retrospectively analyzed. A total 122 non–small-cell received weekly vinorelbine12.5mg/m2, d1,8 carboplatin AUC=2 concurrently radiotherapy 60Gy(CRT group) , group (ECRT which intravenous drip for 1–14 days (every 3 weeks) CRT. assigned at registration 400 mg IH third times per week or no AM during according threshold 25% V20 both lungs. Standard toxicity about end points also collected by CTC4.0. There 76 cases CRT 46 ECRT group. occurrence rate 25.0%, while 13.0%. statistically difference between two groups (P<0.05). And, two-lung V20>25% 31.7% 14.8%. subgroup analysis showed that V20<25% lower than all AM, Both Amifostine may efficiently receiving chemoradiotherapy.